Aeglea Biotherapeutics Inc.’s Lock-Up Period To Expire on October 4th (NASDAQ:AGLE)
Aeglea Biotherapeutics’ (NASDAQ:AGLE) lock-up period is set to expire on Tuesday, October 4th. Aeglea Biotherapeutics had issued 5,000,000 shares in its IPO on April 7th. The total size of the offering was $50,000,000 based on an initial share price of $10.00. After the expiration of Aeglea Biotherapeutics’ lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Separately, Zacks Investment Research lowered Aeglea Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 11th.
Shares of Aeglea Biotherapeutics (NASDAQ:AGLE) traded down 3.61% on Friday, reaching $6.41. The company had a trading volume of 12,245 shares. The company’s market capitalization is $85.96 million. The company’s 50-day moving average is $6.38 and its 200-day moving average is $6.58. Aeglea Biotherapeutics has a one year low of $3.89 and a one year high of $12.75.
Aeglea Biotherapeutics (NASDAQ:AGLE) last issued its earnings results on Tuesday, August 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.03. Equities research analysts predict that Aeglea Biotherapeutics will post ($4.77) earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. VHCP Management II LLC purchased a new position in Aeglea Biotherapeutics during the second quarter worth approximately $1,527,000. Perceptive Advisors LLC purchased a new position in Aeglea Biotherapeutics during the second quarter worth approximately $515,000. Finally, Ghost Tree Capital LLC purchased a new position in Aeglea Biotherapeutics during the second quarter worth approximately $243,000. Hedge funds and other institutional investors own 40.71% of the company’s stock.
About Aeglea Biotherapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.
Receive News & Ratings for Aeglea Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.